Drugs / Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate
Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05656495 | Feb → Nov 2022 | COVID-19 | Promomed, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05656495 ↗ |
| Route | Intramuscular | “for intramuscular administration” NCT05656495 ↗ |